The Role of Pharmacotherapy in Treatment of Meningioma: A Systematic Review
The safety and efficacy of various pharmacotherapeutic regimens on refractory meningiomas have been the focus of investigations. We present a comprehensive review of the previous efforts and the current state of ongoing clinical trials. A PRISMA-compliant review of the MEDLINE and ClinicalTrial.gov...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/2/483 |
| _version_ | 1797444753388732416 |
|---|---|
| author | Ataollah Shahbandi Darsh S. Shah Caroline C. Hadley Akash J. Patel |
| author_facet | Ataollah Shahbandi Darsh S. Shah Caroline C. Hadley Akash J. Patel |
| author_sort | Ataollah Shahbandi |
| collection | DOAJ |
| description | The safety and efficacy of various pharmacotherapeutic regimens on refractory meningiomas have been the focus of investigations. We present a comprehensive review of the previous efforts and the current state of ongoing clinical trials. A PRISMA-compliant review of the MEDLINE and ClinicalTrial.gov databases of the National Library of Medicine were performed. The primary outcomes of interest for included articles were radiographic response, overall survival, progression-free survival, six-month progression-free survival, and adverse events. Overall, 34 completed trials and 27 ongoing clinical trials were eligible. Six-month progression-free survival was reported in 6–100% of patients in the completed studies. Hematological disorders were the most common adverse events. Of the ongoing clinical trials identified, nine studies are phase I clinical trials, eleven are phase II trials, two are phase I and II trials, one is phase II and III, and two trials do not have a designated phase. Currently, there is no effective chemotherapy for refractory or recurrent meningiomas. Several promising targeted agents have been developed and are currently being investigated in the hope of identifying novel therapeutic strategies for the treatment of this pathology. |
| first_indexed | 2024-03-09T13:17:04Z |
| format | Article |
| id | doaj.art-05079348dc4d4391bfc654a52bcd7444 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T13:17:04Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-05079348dc4d4391bfc654a52bcd74442023-11-30T21:34:31ZengMDPI AGCancers2072-66942023-01-0115248310.3390/cancers15020483The Role of Pharmacotherapy in Treatment of Meningioma: A Systematic ReviewAtaollah Shahbandi0Darsh S. Shah1Caroline C. Hadley2Akash J. Patel3Department of Neurological Surgery, School of Medicine, Tehran University of Medical Sciences, Tehran 1416634793, IranDepartment of Neurological Surgery, Dell Medical School, Austin, TX 78712, USADepartment of Neurosurgery, Baylor College of Medicine, Houston, TX 77030, USADepartment of Neurosurgery, Baylor College of Medicine, Houston, TX 77030, USAThe safety and efficacy of various pharmacotherapeutic regimens on refractory meningiomas have been the focus of investigations. We present a comprehensive review of the previous efforts and the current state of ongoing clinical trials. A PRISMA-compliant review of the MEDLINE and ClinicalTrial.gov databases of the National Library of Medicine were performed. The primary outcomes of interest for included articles were radiographic response, overall survival, progression-free survival, six-month progression-free survival, and adverse events. Overall, 34 completed trials and 27 ongoing clinical trials were eligible. Six-month progression-free survival was reported in 6–100% of patients in the completed studies. Hematological disorders were the most common adverse events. Of the ongoing clinical trials identified, nine studies are phase I clinical trials, eleven are phase II trials, two are phase I and II trials, one is phase II and III, and two trials do not have a designated phase. Currently, there is no effective chemotherapy for refractory or recurrent meningiomas. Several promising targeted agents have been developed and are currently being investigated in the hope of identifying novel therapeutic strategies for the treatment of this pathology.https://www.mdpi.com/2072-6694/15/2/483meningeal neoplasmsmeningiomaclinical trialantineoplastic protocolsantineoplastic agentschemoradiotherapy |
| spellingShingle | Ataollah Shahbandi Darsh S. Shah Caroline C. Hadley Akash J. Patel The Role of Pharmacotherapy in Treatment of Meningioma: A Systematic Review Cancers meningeal neoplasms meningioma clinical trial antineoplastic protocols antineoplastic agents chemoradiotherapy |
| title | The Role of Pharmacotherapy in Treatment of Meningioma: A Systematic Review |
| title_full | The Role of Pharmacotherapy in Treatment of Meningioma: A Systematic Review |
| title_fullStr | The Role of Pharmacotherapy in Treatment of Meningioma: A Systematic Review |
| title_full_unstemmed | The Role of Pharmacotherapy in Treatment of Meningioma: A Systematic Review |
| title_short | The Role of Pharmacotherapy in Treatment of Meningioma: A Systematic Review |
| title_sort | role of pharmacotherapy in treatment of meningioma a systematic review |
| topic | meningeal neoplasms meningioma clinical trial antineoplastic protocols antineoplastic agents chemoradiotherapy |
| url | https://www.mdpi.com/2072-6694/15/2/483 |
| work_keys_str_mv | AT ataollahshahbandi theroleofpharmacotherapyintreatmentofmeningiomaasystematicreview AT darshsshah theroleofpharmacotherapyintreatmentofmeningiomaasystematicreview AT carolinechadley theroleofpharmacotherapyintreatmentofmeningiomaasystematicreview AT akashjpatel theroleofpharmacotherapyintreatmentofmeningiomaasystematicreview AT ataollahshahbandi roleofpharmacotherapyintreatmentofmeningiomaasystematicreview AT darshsshah roleofpharmacotherapyintreatmentofmeningiomaasystematicreview AT carolinechadley roleofpharmacotherapyintreatmentofmeningiomaasystematicreview AT akashjpatel roleofpharmacotherapyintreatmentofmeningiomaasystematicreview |